Teva launches Zecuity migraine patch

JERUSALEM — Teva announced the availability of its Zecuity patch (sumatriptan iontophoretic transdermal system), a treatment for acute migraines. The patch is meant to be worn for four hours on the upper arm or thigh and is available in specialty pharmacies by prescription. 

 

The company said the patch is a potential solution for the 73% of migraine sufferers who experience nausea with their migraines. 

 

“Migraine sufferers experiencing nausea as part of their migraine may delay or avoid treatment and may seek non-oral treatment options,” Dr. Michael Hayden, president of Teva’s global research and development and Chief Scientific Officer, said. “At Teva, we are committed to delivering innovative treatments that improve patient care and are proud to offer Zecuity to people looking for a different route to migraine relief.”

 

Alongside Zecuity, Teva also has launched its Migraine Support Solutions hotline to provide patients information about the patch.